Outlook Therapeutics
OTLK
69 hedge funds and large institutions have $32.2M invested in Outlook Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 13 closing their positions.
1,358% more capital invested
Capital invested by funds: $2.21M → $32.2M (+$30M)
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
103% more call options, than puts
Call options by funds: $1.88M | Put options by funds: $926K
28% more funds holding
Funds holding: 54 → 69 (+15)
0.94% more ownership
Funds ownership: 12.68% → 13.61% (+0.94%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$1.95M |
| 2 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.49M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$1.23M |
| 4 |
Jane Street
New York
|
+$884K |
| 5 |
BlackRock
New York
|
+$739K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$858K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$96.7K |
| 3 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$56.4K |
| 4 |
Renaissance Technologies
New York
|
-$52.5K |
| 5 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
-$47.9K |
OTLK Hedge Fund Activity: Q2 2026 in Review
69 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2026, worth a combined $32.2M — up 1,358% from $2.21M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new OTLK positions and 13 closed out — a net gain of 16 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $1.95M. The largest seller was Armistice Capital, exiting entirely with an estimated $858K sold.
- 69 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2026, up from 54 in Q1 2026.
- Funds reported $32.2M of Outlook Therapeutics stock for Q2 2026, up 1,358% quarter-over-quarter.
- 29 funds opened new Outlook Therapeutics positions in Q2 2026 and 13 closed out, a net change of +16 holders.
- The largest Outlook Therapeutics buyer in Q2 2026 was Perceptive Advisors, an estimated $1.95M added.
- The largest Outlook Therapeutics seller in Q2 2026 was Armistice Capital, an estimated $858K sold.
Based on aggregated 13F filings for Q2 2026.